Insilico Medicine and Human Longevity have embarked on a groundbreaking collaboration to develop the first large-scale AI foundation model focused on human longevity science.
This partnership aims to harness the power of artificial intelligence to decode the biological mechanisms of aging, with the goal of enhancing predictive healthcare. The global longevity market, currently valued at approximately $5.3 trillion, is expected to reach $8 trillion by 2030, driven by advancements in AI-driven drug discovery that model aging biology and expedite therapeutic interventions.
Insilico will contribute its expertise in multimodal model development and deep learning, utilizing its MMAI Gym platform to create a robust technical framework. Meanwhile, Human Longevity will provide access to its extensive datasets, which include multi-omic and clinical information gathered from thousands of individuals over the past decade. This integration aims to develop advanced AI models capable of accurately detecting and managing age-related health conditions.
The anticipated foundation models are expected to revolutionize early disease detection and personalized health interventions. Both companies believe that their collaborative efforts will significantly shift healthcare from reactive treatment to proactive longevity science, ultimately paving the way for a new era in medicine.